Translumina launches SPARX Global study for complex coronary artery disease

Translumina has commenced the SPARX Global trial, a multinational, randomized, controlled study designed to evaluate whether a drug-coated balloon (DCB) strategy is preferable to current drug-eluting stents (DES) for patients with complex coronary artery disease. The study aims to provide comparative data on the safety, efficacy, and long-term outcomes of DCB technology, addressing a need for evidence in complex cases.

The trial is expected to yield data that could influence future clinical practice and international guidelines, as randomized evidence for DCB in complex coronary interventions remains limited. Professor Adnan Kastrati of the German Cardiac Center noted that while DES have advanced, permanent metallic implants can be associated with late adverse events, positioning DCB as a potential alternative that leaves no permanent implant.

Professor Florim Cuculi, global principal investigator from Lucerne Cantonal Hospital, stated that SPARX will enroll 1,380 patients across 10 countries. The study's primary endpoint is a one-year device-oriented composite endpoint (DoCE). The trial will compare two paclitaxel-coated balloon technologies directly.

The study will utilize Translumina's Protégé™ DCB. CEO Sudipta Ghosh emphasized that SPARX represents a significant step in the company's commitment to evidence-based innovation, anticipating that the trial will generate high-quality randomized clinical data to define the role of DCBs and support clinicians in providing optimal patient care.